Information About a Doctor or a Possibility of Choosing Doctor's Gender and Attendance to Screening Colonoscopy
NCT ID: NCT01182922
Last Updated: 2011-11-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
EARLY_PHASE1
5100 participants
INTERVENTIONAL
2010-08-31
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This study is designed to assess two factors potentially influencing patients attendance. These two factors are: identification of particular doctor performing examination and the possibility of choosing doctor's gender.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Doctor's Information Invitation
Standard invitation with additional leaflet containing information concerning particular doctor performing the examination, that is: his personal data (name, surname, academic title, workplace, picture) and data concerning experience and achievements of the center where he is employed.
Invitation letter
Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
Gender Preference Invitation
Standard invitation with additional information about possibility of choosing doctor's gender, mentioned below proposed date of examination
Invitation letter
Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
Standard Invitation
Standard invitation without additional information about a doctor or possibility of choosing doctor's gender.
Invitation letter
Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Invitation letter
Invitation letter sent 6 weeks prior to prespecified screening colonoscopy appointment date and followed by reminder letter within 3 weeks if no response is received.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* need for long term attention and nursing services (somatic or psychosocial reasons, mental retardation)
* ongoing cytotoxic treatment or radiotherapy for malignant disease
* severe chronic cardiac or pulmonary disease (NYHA III and IV)
* lifelong anticoagulant treatment
* coronary or cerebrovascular incident requiring hospitalization during the last three months
* residence abroad
* return of unopened letter of invitation and/or reminder, or message of death of the subject (not updated in Population Registry)
* failure to provide written informed consent
* screening colonoscopy within 10 years
55 Years
64 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Maria Sklodowska-Curie National Research Institute of Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jaroslaw Regula, MD, PhD
Role: STUDY_DIRECTOR
Center of Oncology Institute
Krzysztof Skoczylas, MD
Role: PRINCIPAL_INVESTIGATOR
Center of Oncology Institute
Michal F Kaminski, MD
Role: STUDY_CHAIR
Center of Oncology Institute
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
The Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology,
Warsaw, , Poland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CO-I
Identifier Type: -
Identifier Source: org_study_id